Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · IEX Real-Time Price · USD
7.94
+0.24 (3.12%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Tango Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019
Revenue
36.5324.8637.047.6624.65
Revenue Growth (YoY)
46.93%-32.89%383.83%-68.94%-
Gross Profit
36.5324.8637.047.6624.65
Selling, General & Admin
35.530.0317.69.877.54
Research & Development
115.2105.9177.6449.9932.27
Operating Expenses
150.7135.9395.2359.8639.81
Operating Income
-114.17-111.07-58.19-52.2-15.16
Other Expense / Income
-12.56-2.95-0.25-0.23-1.07
Pretax Income
-101.61-108.12-57.94-51.97-14.1
Income Tax
0.130.050.2900
Net Income
-101.74-108.18-58.24-51.97-14.1
Shares Outstanding (Basic)
958862329
Shares Outstanding (Diluted)
958862329
Shares Change
7.69%41.40%94.50%255.37%-
EPS (Basic)
-1.08-1.23-0.94-1.63-1.57
EPS (Diluted)
-1.08-1.23-0.94-1.63-1.57
Free Cash Flow
-119.51-116.77-61.3668.97-26.62
Free Cash Flow Per Share
-1.26-1.33-0.992.16-2.96
Gross Margin
100.00%100.00%100.00%100.00%100.00%
Operating Margin
-312.57%-446.79%-157.09%-681.82%-61.51%
Profit Margin
-278.54%-435.14%-157.21%-678.84%-57.18%
Free Cash Flow Margin
-327.18%-469.72%-165.66%900.84%-108.00%
EBITDA
-95.59-104.09-55.98-50.35-12.62
EBITDA Margin
-261.69%-418.72%-151.12%-657.61%-51.20%
Depreciation & Amortization
6.024.031.971.631.47
EBIT
-101.61-108.12-57.94-51.97-14.1
EBIT Margin
-278.18%-434.92%-156.43%-678.84%-57.18%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).